Dynacure Raises €50M in Series C Financing


Dynacure, a Strasbourg, France-based clinical stage drug development company focused on rare and orphan disorders, closed a €50m Series C financing.

The round was led by Perceptive Advisors, with participation from new investors Bpifrance Large Venture and funds managed by Tekla Capital Management and existing investors Andera Partners, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Kurma Partners and Pontifax. In conjunction with the financing, Henry Skinner, Ph.D., Senior Vice President of Tekla Capital Management, will join the Dynacure board of directors.

The company intends to use the funds to continue to advance its lead program, DYN101, through an ongoing Phase 1 / 2 clinical trial in adults, expand the DYN101 clinical program to include treatment of pediatric patients and to continue to grow operations and its pipeline.

Led by Stephane van Rooijen (M.D. MBA), Chief Executive Officer, Dynacure is a clinical-stage drug development company focused on developing DYN101*, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Myotubular and Centronuclear Myopathies, with Ionis Pharmaceuticals.

The company is also building a complementary research portfolio targeting other orphan disorders. Dynacure also has a corporate office in Philadelphia, PA, USA.

*DYN101 is an investigational antisense oligonucleotide using Ionis’ proprietary antisense technology, designed to modulate the expression of dynamin 2 (DNM2) for the treatment of Myotubular and Centronuclear Myopathies (CNM). Preclinical studies have demonstrated that DYN101 has the potential to be disease modifying in CNM, with compelling preclinical efficacy in treating animal models of XLCNM and ADCNM2,3. Prevention and reversion of the disease was observed with a clear dose-dependent improvement in whole body strength and mice survival. The development plan for DYN101 was designed to be broad and is being investigated for most CNM populations, XLCNM and ADCNM. It has been granted Orphan Drug designations by the US FDA and EMA.



Join the discussion